Efficacy and Safety of Frexalimab In Participants with Relapsing Multiple Sclerosis: 3-Year Results from the Phase 2 Open-Label Extension (CMSC 2026) - Jun 2, 2026 - Abstract #DMT01; Pres time: May 28, 2026; 03:00 PM - 03:20 PM; Location: E216ABCD (Charlotte Convention Center); P2 | "Frexalimab continues to exert sustained reduction in disease activity with favourable safety in pwRMS through 3 years, supporting its further development in phase 3 trials (FREXALT and FREVIVA) as a potential high-efficacy, non-lymphocyte-depleting therapy."
Clinical • P2 data • CNS Disorders • Multiple Sclerosis • CD40LG
|
|
Patrick Vermersch, MD, PhD 1; Stephen Krieger, MD 2; Heinz Wiendl, MD 3; Cristina Granziera, MD, PhD 4; Yang Mao-Draayer, MD, PhD 5; Gary R. Cutter, PhD 6; Oleksandr Kalbus, MD, PhD 7; Ivan Staikov, MD, PhD 8; Michal Dufek, PhD 9; Xavier Montalban, MD, PhD, FEAN, FAAN, FCAHS 10; Stephane Saubadu, MD 11; Xiaodong Luo, PhD 12; Brendan Smyth, MD, PhD 12; Biljana Djukic, PhD 13; Philippe Truffinet, MD 14; Erik Wallstroem, MD, PhD 13; Gavin Giovannoni, MBBCh, PhD 15
|